Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance
Authors
Dagdeviren, SezinJung, Dae Young
Lee, Eunjung
Friedline, Randall H.
Noh, Hye Lim
Kim, Jong Hun.
Patel, Payal R.
Tsitsilianos, Nicholas
Tsitsilianos, Andrew V.
Tran, Duy A.
Tsougranis, George H.
Kearns, Caitlyn C.
Uong, Cecilia P.
Kwon, Jung Yeon.
Muller, Werner
Lee, Ki Won.
Kim, Jason K.
Document Type
Journal ArticlePublication Date
2016-11-14Keywords
Cell BiologyCellular and Molecular Physiology
Endocrinology, Diabetes, and Metabolism
Molecular Biology
Metadata
Show full item recordAbstract
Skeletal muscle insulin resistance is a major characteristic of obesity and type 2 diabetes. Although obesity-mediated inflammation is causally associated with insulin resistance, the underlying mechanism is unclear. Here, we examined the effects of chronic obesity in mice with muscle-specific overexpression of interleukin-10 (MIL10). After 16 weeks of a high-fat diet (HFD), MIL10 mice became markedly obese but showed improved insulin action compared to that of wild-type mice, which was largely due to increased glucose metabolism and reduced inflammation in skeletal muscle. Since leptin regulates inflammation, the beneficial effects of interleukin-10 (IL-10) were further examined in leptin-deficient ob/ob mice. Muscle-specific overexpression of IL-10 in ob/ob mice (MCK-IL10ob/ob) did not affect spontaneous obesity, but MCK-IL10ob/ob mice showed increased glucose turnover compared to that in ob/ob mice. Last, mice with muscle-specific ablation of IL-10 receptor (M-IL10R-/-) were generated to determine whether IL-10 signaling in skeletal muscle is involved in IL-10 effects on glucose metabolism. After an HFD, M-IL10R-/- mice developed insulin resistance with reduced glucose metabolism compared to that in wild-type mice. Overall, these results demonstrate IL-10 effects to attenuate obesity-mediated inflammation and improve insulin sensitivity in skeletal muscle, and our findings implicate a potential therapeutic role of anti-inflammatory cytokines in treating insulin resistance and type 2 diabetes.Source
Mol Cell Biol. 2016 Nov 14;36(23):2956-2966. Print 2016 Dec 1. Link to article on publisher's siteDOI
10.1128/MCB.00181-16Permanent Link to this Item
http://hdl.handle.net/20.500.14038/28804PubMed ID
27644327Related Resources
Link to Article in PubMedRights
Copyright © 2016, American Society for Microbiology.Publisher PDF posted as allowed by the publisher's author rights policy at http://journals.asm.org/site/misc/ASM_Author_Statement.xhtml.ae974a485f413a2113503eed53cd6c53
10.1128/MCB.00181-16